Meghan Fitzgerald, Leslie Norwalk Join Quanta Dialysis Board

QUANTA Dialysis Technologies Ltd. has welcomed two new members to its governing board.

Meghan FitzGerald and Leslie Norwalk will advise the company as it works to improve patient access to dialysis care, care pathways and cost efficiencies.
  
FitzGerald is a global healthcare strategist, investor, academic, and author. She has worked in every domain of healthcare, from front-line patient care through the Fortune 500, while serving as an adjunct professor at Columbia University. Currently, FitzGerald is a private equity investor, serving as an advisor to several firms including Goldman Sachs and Wellspring Capital. Before that, FitzGerald was CEO and managing partner at Letter One’s inaugural health vehicle, where she allocated approximately $4 billion in three years within pharmaceutical services and animal health. FitzGerald has spent nearly 20 years as an operator and strategist working for many prominent healthcare firms, including Merck, Pfizer, and Medco. She was also the executive vice president of strategy, mergers and acquisitions, and health policy at Cardinal Health and a member of the executive committee. In addition to her board appointment at QUANTA, FitzGerald is a member of the Tenet Healthcare Board of Directors.

Norwalk is strategic counsel to Epstein Becker Green P.C., EBG Advisors, and National Health Advisors. She serves as an advisor to several private equity firms and, in addition to QUANTA, sits on the Boards of Directors of Neurocrine Biosciences, Arvinas, NuVasive Inc., ModivCare, Magellan Health, and several privately held healthcare companies. In her prior role with the Bush Administration, Norwalk was acting administrator for the Centers for Medicare & Medicaid Services (CMS), where she managed the day-to-day operations of CMS, State Child Health Insurance Programs, Survey and Certification of healthcare facilities and other federal healthcare initiatives. In addition, Norwalk was the agency’s deputy administrator, responsible for the implementation of the hundreds of changes made under the Medicare Modernization Act, including the Medicare Prescription Drug Benefit.

“We are honored to welcome Meghan and Leslie, two highly respected industry veterans, to QUANTA’s Board,” said Johan de Ruiter, chairman of QUANTA Dialysis Technologies. “The pandemic has emphasized how critical it is for patients and clinicians to have access to flexible, effective dialysis care. The expertise and proven track record Meghan and Leslie bring to QUANTA will be greatly beneficial to our Board as we continue working to bring SC+ directly to every patient in every setting.”
 
QUANTA Dialysis Technologies developed the SC+ hemodialysis system, a portable device with performance comparable to larger, traditional machines. With a simple-to-use and intuitive user interface, SC+ is designed to be operated by a broad range of users to bring dialysis directly to patients. SC+ is commercially available in the United Kingdom for home and facility-based use, and in the United States is cleared by the U.S. Food and Drug Administration for use in chronic and acute care settings.